{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:47:16Z","timestamp":1792684036703,"version":"4.5.0"},"reference-count":4,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"DOI":"10.1182\/blood.2026035159","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:31:59Z","timestamp":1792683119000},"page":"2089-2090","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["One CAR is good; are 2 CARs better?"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"first","affiliation":[{"name":"Lille University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2026102211315223800_bib1","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2025032122","article-title":"Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma","volume":"148","author":"Mailankody","year":"2026","journal-title":"Blood"},{"issue":"9","key":"2026102211315223800_bib2","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2026102211315223800_bib3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026102211315223800_bib4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2025-269","article-title":"Safety and efficacy of AZD0120, a BCMA\/CD19 dual-targeting CAR T-cell therapy, in relapsed\/refractory multiple myeloma: preliminary results from the DURGA-1 phase 1b\/2 study [abstract]","volume":"146","author":"Richard","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/17\/2089\/2595405\/blood_bld-2026-035159-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/17\/2089\/2595405\/blood_bld-2026-035159-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:32:00Z","timestamp":1792683120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/17\/2089\/571565\/One-CAR-is-good-are-2-CARs-better"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":4,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026035159","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,22]]},"published":{"date-parts":[[2026,10,22]]}}}